RWJ 51438
Latest Information Update: 20 Aug 2002
Price :
$50 *
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Johnson & Johnson Pharmaceutical Research & Development LLC
- Class Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 07 Sep 1998 New profile
- 07 Sep 1998 Preclinical development for Thrombosis in USA (Unknown route)